CHINA NATIONAL MEDICINES CORP (600511) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue was RMB 13.878bn, up 0.95% YoY; net income attributable to shareholders was RMB 596.5m, up 9.70%.

• For 9M 2026, revenue rose 3.11% YoY to RMB 40.606bn, while attributable net income fell 1.07% to RMB 1.476bn.

Financial highlights

• Q3 profit before tax was RMB 765.4m, up 8.24% YoY; adjusted attributable net income was RMB 595.7m, up 10.59%.

• 9M profit before tax declined 1.32% YoY to RMB 1.908bn; adjusted attributable net income edged up 0.36% to RMB 1.475bn.

• 9M consolidated net income was RMB 1.490bn versus RMB 1.556bn a year earlier; operating revenue was RMB 40.606bn versus RMB 39.381bn.

• 9M investment income was RMB 424.5m, including RMB 394.2m from associates and joint ventures, versus RMB 441.0m and RMB 411.1m, respectively, a year earlier.

Key financial ratios and metrics

• Q3 basic and diluted EPS were RMB 0.7906, up 9.71% YoY; 9M EPS was RMB 1.9566, down 1.07%.

• Weighted average ROE was 3.12% for Q3, up 0.06 percentage points YoY, and 7.79% for 9M, down 0.71 percentage points.

• Total assets were RMB 36.813bn at Sep. 30, 2026, up 0.35% from year-end 2025; equity attributable to shareholders was RMB 19.408bn.